Ghent University Academic Bibliography

Journal Article
A1
open access

Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency

Emilia J. Kozyra, Victor B. Pastor, Stylianos Lefkopoulos, Sushree S. Sahoo, Hauke Busch, Rebecca K. Voss, Miriam Erlacher, Dirk Lebrecht, Enikoe A. Szvetnik, Shinsuke Hirabayashi, et al.

(2020) LEUKEMIA.

Add to list

PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis

E. G. Garcia, A. Veloso, M. L. Oliveira, J. R. Allen, S. Loontiens, D. Brunson, D. Do, C. Yan, R. Morris, S. Iyer, et al.

(2020) LEUKEMIA.

Add to list

A novel TLX1-driven T-ALL zebrafish model : comparative genomic analysis with other leukemia models

Siebe Loontiens (UGent) , Suzanne Vanhauwaert (UGent) , Lisa Depestel (UGent) , Givani Dewyn (UGent) , Wouter Van Loocke (UGent) , Finola E. Moore, Elaine G. Garcia, Lance Batchelor, Chiara Borga, Barbara Squiban, et al.

(2020) LEUKEMIA. 34(12). p.3398-3403

Add to list

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

G. J. Ossenkoppele, D. A. Breems, G. Stuessi, Y. Van Norden, M. Bargetzi, B. J. Biemond, P. A von dem Borne, Y. Chalandon, J. Cloos, D. Deeren, et al.

(2020) LEUKEMIA. 34(7). p.1751-1759

Add to list

Journal Article
A1
open access

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Alessandra Tedeschi, Osnat Bairey, Peter Hillmen, Steven E. Coutre, Stephen Devereux, et al.

(2020) LEUKEMIA. 34(3). p.787-798

Add to list

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia

Stephan Stilgenbauer, Therese Aurran Schleinitz, Barbara Eichhorst, Fabian Lang, Fritz Offner (UGent) , Jean-Francois Rossi, Wilfried Schroyens, Eric Van den Neste, Loic Ysebaert, Ute von Wangenheim, et al.

(2019) LEUKEMIA. 33(10). p.2531-2535

Add to list

Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia

Elaine G Garcia, Sowmya Iyer, Sara P Garcia, Siebe Loontiens (UGent) , Ruslan I Sadreyev, Franki Speleman (UGent) and David M Langenau

(2018) LEUKEMIA. 32(8). p.1860-1865

Add to list

Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia : results of the EORTC CLG 58881 and 58951 trials

C Piette, S Suciu, E Clappier, Y Bertrand, S Drunat, S Girard, K Yakouben, G Plat, N Dastugue, F Mazingue, et al.

(2018) LEUKEMIA. 32(1). p.244-248

Add to list

The NF1 hotspot in acute myeloid leukemia : what’s in a name?

Karl Vandepoele (UGent) , Joni Van der Meulen (UGent) and Barbara Denys (UGent)

(2018) LEUKEMIA. 32(12). p.2715-2715

Add to list

Journal Article
A1
open access

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Robert J Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Lionel Karlin, Tadeusz Robak, Douglas E Gladstone, Philipp le Coutre, Sascha Dietrich, Mirjana Gotic, et al.

(2018) LEUKEMIA. 32(8). p.1768-1777

Academic Bibliography

Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency

PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis

A novel TLX1-driven T-ALL zebrafish model : comparative genomic analysis with other leukemia models

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia

Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia

Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia : results of the EORTC CLG 58881 and 58951 trials

The NF1 hotspot in acute myeloid leukemia : what’s in a name?

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Contents

Support

Contact